Protection Against Marburg Virus Using a Recombinant VSV-Vaccine Depends on T and B Cell Activation
Marburg virus (MARV) is the causative agent of hemorrhagic fever outbreaks with high case fatality rates. Closely related to Ebola virus, MARV is a filamentous virus with a negative-sense, single-stranded RNA genome. Although extensive studies on filovirus countermeasures have been conducted, there...
Main Authors: | Andrea Marzi, Andrea R. Menicucci, Flora Engelmann, Julie Callison, Eva J. Horne, Friederike Feldmann, Allen Jankeel, Heinz Feldmann, Ilhem Messaoudi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.03071/full |
Similar Items
-
Marburg virus pathogenesis – differences and similarities in humans and animal models
by: Kyle Shifflett, et al.
Published: (2019-12-01) -
Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection
by: Andrea R. Menicucci, et al.
Published: (2019-05-01) -
Experimental Vaccines for Prevention of Marburg Hemorrhagic Fever and Animal Models for Studying Pathogenesis
by: N. V. Volkova, et al.
Published: (2018-10-01) -
Development of a T7-Independent MARV Minigenome System
by: Bert Vanmechelen, et al.
Published: (2020-06-01) -
Obtaining Recombinant Antigens for the Development of Serological Diagnosis of Marburg Fever
by: N. V. Volkova, et al.
Published: (2021-02-01)